These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36044733)

  • 21. Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors .
    Podoll T; Pearson PG; Kaptein A; Evarts J; de Bruin G; Emmelot-van Hoek M; de Jong A; van Lith B; Sun H; Byard S; Fretland A; Hoogenboom N; Barf T; Slatter JG
    J Pharmacol Exp Ther; 2023 Jan; 384(1):173-186. PubMed ID: 36310034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes.
    Liu J; Guiadeen D; Krikorian A; Gao X; Wang J; Babu Boga S; Alhassan AB; Yu W; Selyutin O; Yu Y; Anand R; Xu J; Kelly J; Duffy JL; Liu S; Yang C; Wu H; Cai J; Bennett C; Maloney KM; Tyagarajan S; Gao YD; Fischmann TO; Presland J; Mansueto M; Xu Z; Leccese E; Zhang-Hoover J; Knemeyer I; Garlisi CG; Stivers P; Brandish PE; Hicks A; Kim R; Kozlowski JA
    Bioorg Med Chem Lett; 2020 Sep; 30(17):127390. PubMed ID: 32738973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Second-generation inhibitors of Bruton tyrosine kinase.
    Wu J; Liu C; Tsui ST; Liu D
    J Hematol Oncol; 2016 Sep; 9(1):80. PubMed ID: 27590878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Bruton's tyrosine kinase inhibitors.
    Zou Y; Xiao J; Tu Z; Zhang Y; Yao K; Luo M; Ding K; Zhang Y; Lai Y
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3052-3059. PubMed ID: 27210433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modeling the Binding and Conformational Energetics of a Targeted Covalent Inhibitor to Bruton's Tyrosine Kinase.
    Awoonor-Williams E; Rowley CN
    J Chem Inf Model; 2021 Oct; 61(10):5234-5242. PubMed ID: 34590480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Practical management of chronic lymphocytic leukemia with acalabrutinib.
    Kuss B; Nagarajan C; Hsieh WS; Cheah CY
    Leuk Lymphoma; 2022 Dec; 63(12):2785-2794. PubMed ID: 35852229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aberrantly expressed Bruton's tyrosine kinase preferentially drives metastatic and stem cell-like phenotypes in neuroblastoma cells.
    Pikatan NW; Liu YL; Bamodu OA; Hsiao M; Hsu WM; Haryana SM; Sutaryo ; Chao TY; Yeh CT
    Cell Oncol (Dordr); 2020 Dec; 43(6):1067-1084. PubMed ID: 32705581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
    Ghia P; Dlugosz-Danecka M; Scarfò L; Jurczak W
    Leuk Lymphoma; 2021 May; 62(5):1066-1076. PubMed ID: 33427570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of 1-Amino-1
    Ma C; Li Q; Zhao M; Fan G; Zhao J; Zhang D; Yang S; Zhang S; Gao D; Mao L; Zhu L; Li W; Xu G; Jiang Y; Ding Q
    J Med Chem; 2021 Nov; 64(21):16242-16270. PubMed ID: 34672559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs?
    Busygina K; Denzinger V; Bernlochner I; Weber C; Lorenz R; Siess W
    Thromb Haemost; 2019 Aug; 119(8):1212-1221. PubMed ID: 31087308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A uniquely distributed purpuric drug eruption from acalabrutinib.
    Truong K; Bhattacharyya A; Kim J; Wells J
    Australas J Dermatol; 2022 May; 63(2):e142-e144. PubMed ID: 35072264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
    Qiu H; Liu-Bujalski L; Caldwell RD; Follis AV; Gardberg A; Goutopoulos A; Grenningloh R; Head J; Johnson T; Jones R; Mochalkin I; Morandi F; Neagu C; Sherer B
    Bioorg Med Chem Lett; 2018 Sep; 28(17):2939-2944. PubMed ID: 30122225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice.
    Rip J; de Bruijn MJW; Neys SFH; Singh SP; Willar J; van Hulst JAC; Hendriks RW; Corneth OBJ
    Eur J Immunol; 2021 Sep; 51(9):2251-2265. PubMed ID: 34323286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
    Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A
    Elife; 2020 Nov; 9():. PubMed ID: 33226337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions.
    Series J; Garcia C; Levade M; Viaud J; Sié P; Ysebaert L; Payrastre B
    Haematologica; 2019 Nov; 104(11):2292-2299. PubMed ID: 30819914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
    Byrd JC; Harrington B; O'Brien S; Jones JA; Schuh A; Devereux S; Chaves J; Wierda WG; Awan FT; Brown JR; Hillmen P; Stephens DM; Ghia P; Barrientos JC; Pagel JM; Woyach J; Johnson D; Huang J; Wang X; Kaptein A; Lannutti BJ; Covey T; Fardis M; McGreivy J; Hamdy A; Rothbaum W; Izumi R; Diacovo TG; Johnson AJ; Furman RR
    N Engl J Med; 2016 Jan; 374(4):323-32. PubMed ID: 26641137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton's tyrosine kinase inhibitors.
    Sakthivel S; Habeeb SKM
    J Biomol Struct Dyn; 2018 Dec; 36(16):4320-4337. PubMed ID: 29293382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management.
    Fancher KM; Pappacena JJ
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):507-515. PubMed ID: 32940733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting Bruton's Tyrosine Kinase in CLL.
    Ahn IE; Brown JR
    Front Immunol; 2021; 12():687458. PubMed ID: 34248972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.